FFA
LXRX icon

Farther Finance Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Farther Finance Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4 Hold
2
– – ﹤0.01% 6119
2026
Q2 		$5 Sell
2
-253
-99% -$493 ﹤0.01% 5946
2026
Q1 		$418 Sell
255
-2,500
-91% -$3.63K ﹤0.01% 5310
2025
Q4 		$3.17K Buy
2,755
+1,500
+120% +$2.06K ﹤0.01% 4510
2025
Q3 		$1.69K Buy
1,255
+253
+25% +$287 ﹤0.01% 4195
2025
Q2 		$948 Buy
1,002
+1,000
+50,000% +$648 ﹤0.01% 3913
2025
Q1 		$1 Hold
2
– – ﹤0.01% 4256
2024
Q4 		$1 Hold
2
– – ﹤0.01% 3995
2024
Q3 		$3 Hold
2
– – ﹤0.01% 3971
2024
Q2 		$3 Hold
2
– – ﹤0.01% 3803
2024
Q1 		$5 Hold
2
– – ﹤0.01% 3577
2023
Q4 		$3 Buy
+2
New +$2 ﹤0.01% 3536

Other funds holding LXRX

SFL
Scheeler Financial LLC West Chester, Ohio $132M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's LXRX Position: Q3 2026 in Review

Farther Finance Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q3 2026 at 2 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #6119.

Farther Finance Advisors first reported a position in LXRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $3.17K in Q4 2025. 5 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Farther Finance Advisors held 2 shares of Lexicon Pharmaceuticals worth $4 as of Q3 2026.
  • Farther Finance Advisors left its Lexicon Pharmaceuticals share count unchanged in Q3 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #6119 holding.
  • Farther Finance Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Lexicon Pharmaceuticals position peaked at $3.17K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.